Sample collection for a COVID-19 seroprevalence study started on 02 December 2020 in the camps. The aim of this study is to estimate the population-level exposure to SARS-CoV-2 across the Rohingya camps. This will be measured by visiting randomly selected households and selecting one participant from the household to provide a blood sample. The study is based on WHO’s “UNITY protocol” for standardized sero-epidemiological investigations and aims to inform an evidence-based planning for the COVID-19 response in 2021. It is led by the Institute of Epidemiology Disease Control and Research (IEDCR) and supported by WHO, UNHCR, BDRCS, FH, RI, RTMI, BRAC and IOM. More than 1000 refugees participated in the study to date. The IEDCR Field Laboratory is playing a key role in testing the samples collected for the seroprevalence study in the Rohingya camps. Testing was initiated this week after deployment of ELISA kits for detection of antibodies against COVID-19.
The health sector coordination team with support from a peer review team, formed by representatives from key national and international NGOs and UN agencies, recommended 26 projects from 26 partners for the Joint Response Plan (JRP) 2021.
SUBJECT IN FOCUS: Setting up Severe Acute Respiratory Infection Isolation and Treatment Centres (SARI ITCs) in a complex setting